Drug repurposing for Alzheimer's disease and other neurodegenerative disorders.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39971900.
- Also identified by DOI 10.1038/s41467-025-56690-4 and PMC identifier 11840136.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Repurposed drugs provide a rich source of potential therapies for Alzheimer's disease (AD) and other neurodegenerative disorders (NDD). Repurposed drugs have information from non-clinical studies, phase 1 dosing, and safety and tolerability data collected with the original indication. Computational approaches, "omic" studies, drug databases, and electronic medical records help identify candidate therapies. Generic repurposed agents lack intellectual property protection and are rarely advanced to late-stage trials for AD/NDD. In this review we define repurposing, describe the advantages and challenges of repurposing, offer strategies for overcoming the obstacles, and describe the key contributions of repurposing to the drug development ecosystem.
Medical subject headings
- Drug Repositioning
- Alzheimer Disease
- Neurodegenerative Diseases